Your Immune System Has Been Keeping Score: The Blood Test That Could Predict Alzheimer’s Risk Years in Advance

A landmark study of nearly 400,000 patients reveals that a routine number on your standard blood panel may signal Alzheimer’s disease risk years before the first memory lapses appear.

Presented By Our Partners

Most people get a complete blood count at some point in their lives: a standard test ordered to check for infection, anemia, or a dozen other conditions. The results come back as a table of numbers, and unless something is flagged, most patients never look twice at it. But new research from NYU Langone Health suggests that one ratio buried in that familiar table may be doing something remarkable: quietly tracking your brain’s inflammatory future, years before your first forgotten word.

The finding, published April 3, 2026 in the journal Alzheimer’s & Dementia, is the largest human study ever to link the neutrophil-to-lymphocyte ratio to dementia risk. Researchers analyzed data from nearly 400,000 patients across two major healthcare systems and found a consistent, statistically significant association between elevated NLR and the later development of Alzheimer’s disease and related dementias. The implications reach far beyond immunology. They touch the way medicine thinks about early detection, preventive neurology, and who gets screened before it’s too late.

What Is the Neutrophil-to-Lymphocyte Ratio?

The NLR is exactly what it sounds like: the ratio of neutrophils to lymphocytes in your blood. Both are white blood cells, but they represent opposite arms of the immune system. Neutrophils are the first responders, the frontline soldiers that rush to a site of infection or injury and deploy inflammatory signals to neutralize threats. Lymphocytes are the adaptive immune cells: T cells, B cells, and natural killer cells that mount more targeted, long-term immune responses.

In a healthy immune system, these two populations stay roughly balanced. But when the body is under chronic stress, whether from infection, metabolic disease, psychological strain, or persistent low-grade inflammation, neutrophils tend to rise relative to lymphocytes. The NLR climbs. And according to this new research, that climbing number appears to carry information about the brain’s inflammatory burden.

Calculating NLR requires nothing beyond a standard CBC with differential, a test already ordered millions of times each year in primary care offices, hospitals, and urgent care clinics across the country. No new biomarker panel. No costly imaging. No lumbar puncture. The tool is already in the clinic. What has been missing, until now, is evidence that it belongs in the conversation about brain health.

The Study: Scale, Design, and Findings

The new research was led by Dr. Tianshe (Mark) He, a data scientist in the Department of Psychiatry at NYU Grossman School of Medicine, with co-senior authorship from Dr. Jaime Ramos-Cejudo, an assistant professor in the Departments of Psychiatry and Neurology at NYU Grossman who is also affiliated with the VA Boston Healthcare System’s Cooperative Studies Program.

The team drew on two independent patient cohorts. The first included approximately 285,000 patients treated across four NYU Langone hospitals. The second included roughly 85,000 patients from the Veterans Health Administration. Together, the datasets represent one of the most diverse and expansive analyses of immune markers and dementia risk ever conducted in a real-world healthcare setting.

In both cohorts, a higher NLR was significantly associated with increased risk of future Alzheimer’s disease and related dementias. In the NYU cohort, the hazard ratio for dementia was 1.07 to 1.15 (95% confidence interval). In the VA cohort, the hazard ratio reached 1.21 (95% CI, 1.10 to 1.34). These numbers, while modest for any single individual, translate to meaningful population-level risk, particularly given how common elevated NLR values are in the aging population.

Subgroup analyses revealed that the association was stronger among female patients and Hispanic patients. The researchers noted that while the reasons behind the demographic differences are not yet fully understood, they may reflect a combination of genetic variation, hormonal influences on immune function, and systemic disparities in healthcare access that allow inflammatory conditions to go unmanaged for longer periods.

Why Inflammation? Why Neutrophils?

The idea that inflammation is central to Alzheimer’s disease is not new. Neuroinflammation has been a focus of Alzheimer’s research for decades, with growing evidence that chronic immune activation in the brain accelerates the deposition of amyloid plaques, promotes tau tangles, and contributes to synaptic deterioration. What has been less clear is the specific role of peripheral immune cells, those circulating in the blood rather than residing in the brain, in driving or reflecting this process.

Neutrophils have emerged as a compelling suspect. Although their primary job is rapid response to injury and infection, they also have a darker side. When chronically elevated or dysregulated, neutrophils can cause collateral tissue damage, particularly at the vascular level. Researchers have found neutrophil-related inflammation in the brain pathology of Alzheimer’s patients, and studies in mouse models have demonstrated that neutrophils actively accelerate disease progression when they infiltrate brain tissue.

The blood-brain barrier, which normally keeps peripheral immune cells out of the central nervous system, becomes increasingly permeable with age. Elevated NLR may signal both systemic inflammation and a greater likelihood that this barrier has been compromised, allowing neutrophils to penetrate brain tissue and contribute directly to neurodegeneration.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

Dr. Ramos-Cejudo put it plainly in the NYU Langone press release: “Although neutrophils are important for healing wounds, they can cause the sort of tissue damage at the vascular level that has been seen in Alzheimer’s and dementia.”

The Critical Window: Why Early Detection Matters So Much

Alzheimer’s disease is not an event. It is a decades-long biological process. The toxic protein aggregates associated with the disease, amyloid-beta plaques and tau tangles, begin accumulating in the brain roughly 15 to 20 years before the first clinical symptoms of cognitive impairment appear. By the time someone forgets a close friend’s name or gets disoriented in a familiar neighborhood, the pathological cascade has been underway for almost a generation.

This preclinical window has been the central challenge and the central opportunity of Alzheimer’s research. The window is wide enough that interventions introduced early, before widespread neuronal death, have a real chance to change the disease trajectory. But identifying who is in that window, years or decades before symptoms, has been extraordinarily difficult without expensive or invasive testing.

The NLR finding addresses this challenge directly. If a number routinely collected from existing blood work can help flag patients who warrant closer monitoring, earlier cognitive screening, or lifestyle intervention, that is a tool with enormous reach. Millions of Americans already have NLR data sitting in their medical records from previous bloodwork. The question is whether their physicians know to look at it in the context of brain health.

“The neutrophil to lymphocyte ratio can contribute to gateway diagnostic tools for people at risk of developing Alzheimer’s and dementia,” Dr. He said, “so they can get more in-depth testing and interventions long before they experience cognitive decline.”

This Is Not the First Signal

The NYU Langone study did not arrive in a vacuum. Prior research had already hinted at the NLR-dementia connection, though at far smaller scales. The Framingham Heart Study, one of the most respected long-running cardiovascular cohorts in the world, previously found an association between neutrophil-to-lymphocyte ratio and subsequent dementia risk. A 2024 meta-analysis published in PLOS ONE synthesized data from multiple studies and concluded that elevated NLR was consistently associated with both the presence of Alzheimer’s disease and markers of amyloid pathology in cognitively healthy older adults.

What the new NYU and VA analysis provides is scale and real-world validation. Earlier studies drew from thousands of participants in controlled research settings. This study drew from nearly 400,000 patients who received routine clinical care across two of the country’s largest healthcare systems, confirming that the NLR signal holds up in the messy, heterogeneous world of actual medicine.

The convergence of evidence from multiple independent cohorts, using different methodologies, in different populations, is the kind of scientific agreement that typically marks the moment when a biomarker moves from research curiosity to clinical utility.

What Elevated NLR Does and Does Not Tell You

It is worth being precise about what this research does and does not claim. An elevated NLR is not a diagnosis. It is not proof that Alzheimer’s disease is developing. A high NLR can result from infection, autoimmune conditions, stress, medications, and a range of other causes entirely unrelated to neurodegeneration. Many people with elevated NLR will never develop dementia.

What the research establishes is a probabilistic signal: people with chronically elevated NLR, particularly when no acute infection or other obvious cause explains the elevation, face statistically higher odds of developing Alzheimer’s and related dementias over the following years. In combination with other known risk factors, such as family history, APOE-e4 carrier status, cardiovascular disease, type 2 diabetes, sleep disorders, and low cognitive reserve, an elevated NLR could meaningfully change a clinician’s assessment of a patient’s overall dementia risk profile.

The researchers frame it as a gateway: a low-cost, widely available indicator that can identify candidates for more comprehensive evaluation. Those evaluations might include cognitive testing, advanced blood-based biomarkers such as plasma amyloid and tau, PET imaging, or enrollment in preventive intervention programs while the brain still has significant capacity for protection and repair.

The Broader Picture: Alzheimer’s and the Immune Revolution

The NLR study is part of a broader conceptual revolution underway in Alzheimer’s research: the recognition that the disease is not simply a story of protein buildup in the brain, but a complex interaction between the central nervous system and the body’s immune machinery. Peripheral inflammation, metabolic dysfunction, gut microbiome imbalances, and systemic immune dysregulation all appear to contribute to the brain’s vulnerability to neurodegeneration.

This shift has profound implications. It means that interventions targeting systemic inflammation, not just brain-specific pathology, may reduce Alzheimer’s risk. Cardiovascular disease, chronic stress, obesity, and insulin resistance are not just heart problems or metabolic problems. They are brain problems too, mediated in part through the same inflammatory pathways that elevate the NLR and compromise the blood-brain barrier.

From the perspective of the research community, lifestyle factors that reduce systemic inflammation, including regular physical activity, a diet low in ultra-processed foods, sufficient sleep, and stress management, are not soft wellness advice. They are mechanistically plausible strategies for reducing the immune-driven component of Alzheimer’s risk. The NLR provides a potential biomarker for tracking whether those interventions are actually working at the immune level.

What Comes Next

The NYU Langone team is continuing its research, exploring additional inflammatory markers and refining the predictive models to better account for confounding variables. Key questions remain about what NLR threshold reliably signals elevated dementia risk, how frequently it should be measured, and how it performs in combination with other biomarkers.

There is also important work ahead on the demographic disparities the study identified. The stronger association seen in Hispanic patients and female patients warrants dedicated investigation, both to understand the biological mechanisms at play and to ensure that any clinical tools developed from this research serve all populations equitably.

Longer term, researchers hope that findings like these will contribute to a comprehensive, multi-layered early detection framework for Alzheimer’s: one that integrates accessible blood markers, lifestyle risk factors, genetic data, and advanced neuroimaging into a coherent picture of an individual’s brain health trajectory, decades before the disease becomes symptomatic.

What This Means for You

If you are interested in protecting your brain for the long term, the most important takeaway from this research is not to panic over a single blood test result. NLR is one signal among many, and context matters enormously.

Here is what you can do right now. First, ask your physician about your NLR at your next annual blood panel. A standard CBC with differential gives you this number, and it is often ordered as part of routine physicals. If your NLR is elevated and there is no obvious acute explanation, that is worth discussing in the context of your overall health, not as a diagnosis, but as a data point.

Second, focus on the interventions that reduce systemic inflammation across the board. The same lifestyle factors that protect cardiovascular health appear to protect the brain through shared inflammatory pathways. Regular resistance training and cardiovascular exercise lower neutrophil activation and improve immune regulation. A whole-food, fiber-rich diet reduces inflammatory cytokines and supports gut microbiome diversity. Seven to nine hours of quality sleep clears metabolic waste from the brain through the glymphatic system. Stress management practices including breathwork and meditation reduce cortisol-driven immune dysregulation.

Third, if you carry known risk factors for Alzheimer’s, including family history, APOE-e4 carrier status, or the presence of cardiometabolic disease, speak with your physician about comprehensive cognitive screening and early monitoring. The preclinical window for Alzheimer’s is wide, and it is also the window where intervention is most likely to matter.

The blood test that has been part of routine medicine for decades may have just revealed a new purpose. The science is telling us that the immune system and the aging brain are not separate stories. They are the same story, written in the same cells, playing out over the same decades. Paying attention to one means paying attention to both.

Source: He T, et al. “Neutrophil inflammation metrics are associated with the risk of future dementia in large data from NYU Langone Hospitals and the Veterans Health Administration.” Alzheimer’s & Dementia. Published April 3, 2026. DOI: 10.1002/alz.71335.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.